Abstract
A patient with inflammatory breast carcinoma (IBC) diagnosed in the left breast responded to cisplatin and was treated with radical mastectomy and adjuvant therapy. Two years later C-erbB2-positive IBC was diagnosed in the right breast, and was treated with mastectomy and radiotherapy. Two years later skin metastases appeared, and trastuzumab was started initially as monotherapy, and later with paclitaxel and capecitabine. More than 12 years after diagnosis and 7 years after trastuzumab was started, the patient remains in complete clinical remission on trastuzumab and capecitabine.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / pathology
-
Capecitabine
-
Carcinoma, Ductal, Breast / drug therapy*
-
Carcinoma, Ductal, Breast / metabolism
-
Carcinoma, Ductal, Breast / secondary
-
Cisplatin / adverse effects
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / analogs & derivatives
-
Humans
-
Mastectomy
-
Neoplasms, Second Primary
-
Paclitaxel / administration & dosage
-
Receptor, ErbB-2 / metabolism*
-
Remission Induction
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / mortality
-
Skin Neoplasms / secondary
-
Survival Rate
-
Trastuzumab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Deoxycytidine
-
Capecitabine
-
Receptor, ErbB-2
-
Trastuzumab
-
Paclitaxel
-
Cisplatin
-
Fluorouracil